How does Pacira BioSciences, Inc. turn longer – lasting local anesthesia into a hospital revenue and opioid – reduction play?
Pacira BioSciences, Inc. commercializes extended – release local anesthetics for post – surgical pain, selling into hospitals and surgery centers while capturing reimbursement and formulary placement. In 2025 it reported sustained sales growth driven by expanded OR adoption and higher average selling price per dose.
Pacira's revenue logic rests on per – procedure dosing, hospital purchasing contracts, and portfolio expansion under its 5x30 growth plan; durable uptake ties to reduced opioid prescriptions and shorter stays. See Pacira SWOT Analysis.
What Does Pacira Actually Sell?
Pacira BioSciences sells non-opioid pain management products focused on extended-release local analgesics and targeted nerve treatments; its main offering is EXPAREL, a long-acting liposomal bupivacaine for postsurgical pain, supplemented by ZILRETTA for osteoarthritis knee pain and iovera cryoneurolysis to cool nerves and reduce pain.
Core product lineup
EXPAREL Pacira is a liposomal bupivacaine injectable suspension that releases bupivacaine over up to 72 hours to reduce postoperative opioid use; ZILRETTA is an extended – release triamcinolone formulation for knee osteoarthritis; iovera is a cryoneurolytic system for targeted peripheral nerve cooling and temporary pain relief.
Primary customers
Pacira company sells to hospitals, ambulatory surgery centers, orthopedic and pain clinics, and anesthesiologists and surgeons seeking opioid-sparing perioperative and chronic pain protocols; hospital administrators prioritize cost and throughput gains.
Value delivered
Customers gain extended postsurgical analgesia, fewer opioid-related adverse events, faster mobilization, and potential shorter stays-Pacira markets EXPAREL as lowering total cost of care via reduced opioid consumption and streamlined discharges.
Why customers choose it
Clinicians pick Pacira products for the distinct delivery technologies: multivesicular liposomes for sustained bupivacaine release, extended corticosteroid residence for ZILRETTA, and focal cryoneurolysis for iovera-these are harder to substitute than standard single – dose local anesthetics.
As of fiscal 2025 Pacira BioSciences reported total revenue of $640 million, with EXPAREL accounting for roughly 70% of product revenue; clinical and payer evidence cite reduced opioid use up to 48-72 hours post-op for EXPAREL in multiple trials, while ZILRETTA generated meaningful orthopedic clinic uptake after its 2017 FDA approval. See the History of Pacira Company Explained for background on regulatory milestones and product approvals.
Pacira SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Does Pacira Run Day to Day?
Pacira BioSciences runs day-to-day as a focused pharmaceutical pipeline: R&D-led product development, in-house liposomal manufacturing, and tiered distribution via wholesalers to hospitals and surgical centers. Operations center on scaling EXAPREL and ZILRETTA reach while executing the 5x30 strategy to treat over 3,000,000 patients annually by 2030.
Operating model: R&D, make, distribute
Pacira BioSciences runs a classic pharmaceutical pipeline: research and development of liposomal bupivacaine and steroid formulations, proprietary manufacturing, and tiered distribution to institutional buyers. Day-to-day teams manage clinical programs, regulatory filings, and supply chain to keep hospitals stocked.
Product delivery: wholesalers to clinicians
Products flow from Pacira's manufacturing sites to large wholesalers and group purchasing organizations, then to hospitals, ambulatory surgery centers, and physician offices. Clinicians order EXAPREL Pacira and ZILRETTA through established hospital procurement and specialty distributors.
Production and development: proprietary liposomal tech
Pacira maintains proprietary liposomal bupivacaine formulation processes and runs clinical trials-EXAPREL clinical programs and ZILRETTA studies-to expand indications. The company outsources select regional regulatory and commercialization tasks, for example with LG Chem in South Korea and Thailand for 2026.
Sales and distribution: multi-channel network
Primary sales channels are large wholesalers, GPO contracts, and direct hospital accounts; commercial reach is amplified via partnerships such as the J&J MedTech agreement that expanded ZILRETTA U.S. reach. Pricing and reimbursement work through hospital formularies and procedure-level contracting.
Key assets and partnerships: manufacturing and alliances
Key assets include proprietary liposomal manufacturing capabilities, regulatory dossiers, and commercial partnerships. Strategic alliances-J&J MedTech for sales, LG Chem for APAC commercialization-let Pacira scale without commensurate fixed-cost increases.
What makes it work: focused pipeline and partnerships
Operational efficiency rests on a focused product set (EXAPREL Pacira, ZILRETTA), specialized manufacturing, and outsized leverage from distribution partners. The 5x30 strategy channels commercial and clinical resources to volume growth while keeping SG&A growth controlled.
Day-to-day operational summary for Pacira BioSciences
Pacira BioSciences runs daily operations by coordinating R&D and manufacturing of liposomal bupivacaine, managing wholesale distribution to hospitals and ASC customers, and executing partnership-driven commercial expansion to meet the 5x30 goal.
- The core operating model is an R&D-to-manufacturing pharmaceutical pipeline focused on liposomal formulations
- Products are delivered via large wholesalers, GPO contracts, and hospital procurement systems
- Major partnerships (J&J MedTech, LG Chem) and proprietary manufacturing support national and regional scale
- The model works efficiently because partnerships expand reach while Pacira keeps fixed overhead focused on R&D and manufacturing
For strategic direction and more context on Pacira partnerships and the 5x30 plan, see Where Pacira Company Is Going
Pacira PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Does Money Come In at Pacira?
Pacira BioSciences earns most revenue by selling its drug products to wholesalers and hospitals; payment flows from insurers (Medicare/Medicaid and private payers) through reimbursement. EXPAREL is the dominant product, with ZILRETTA, iovera, and modest royalties rounding out sales.
Main revenue: EXPAREL Pacira sales
EXPAREL generated 575.1 million USD in 2025 and accounts for the largest share of Pacira company revenue because it is the firm's flagship non-opioid, liposomal bupivacaine surgical analgesic used broadly in hospitals.
Additional revenue: ZILRETTA, iovera, royalties
ZILRETTA produced 116.6 million USD and iovera 24.2 million USD in 2025; smaller income streams include royalties and other sales from partnerships and legacy assets.
Pricing and monetization model
Pacira sells products via one-time product sales to wholesalers and hospitals; hospitals seek reimbursement from CMS or private insurers, so realized price depends on negotiated rates and payer coverage.
What drives revenue most
Volume and product mix drive revenue-surgical adoption of EXPAREL, payer reimbursement levels, and hospital purchasing scale determine top-line performance; pricing power in hospital formularies also matters.
How money comes in at Pacira BioSciences
Pacira converts clinical use into cash by selling EXPAREL, ZILRETTA, and iovera to distributors and hospitals, which in turn collect reimbursement from CMS and private insurers; management projects 2026 revenue of 745-770 million USD with EXPAREL at 600-620 million USD.
- EXPAREL: main revenue stream, 575.1 million USD in 2025
- ZILRETTA and iovera: secondary monetization, 116.6 million USD and 24.2 million USD in 2025
- Monetization model: one-time product sales to wholesalers/hospitals with payer reimbursement
- Strongest driver: surgical adoption and payer reimbursement rates for EXPAREL
For context on customers and market positioning see Who Pacira Company Serves.
Pacira SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Makes Pacira's Model Strong or Fragile?
Pacira BioSciences' model is strong because EXPAREL Pacira sits behind a long patent runway through 2039 and benefits from secular moves toward non – opioid pain management, but fragile due to extreme customer concentration and active shareholder pressure that could force near – term strategic disruption.
Patent protection and secular tailwinds
EXPAREL's exclusivity extended by a patent settlement with Fresenius secures primary cash flow through 2039, and growing clinical and guideline support for opioid-sparing care drives durable demand for Pacira products and treatments.
Clinical differentiation and pricing power
Liposomal bupivacaine (EXPAREL Pacira) offers a distinct delivery mechanism that reduces opioid use; clinical trial efficacy results and hospital protocol adoption give the brand pricing and formulary leverage versus plain bupivacaine.
Wholesaler concentration and revenue risk
Approximately 78-79% of revenue flows through the top three wholesalers, creating procurement and payment dependence that could amplify order volatility or negotiating pressure on price and terms.
Corporate governance and activist pressure
Activist investor DOMA Perpetual Capital Management has pushed for board changes and a sale process, raising governance risk and potential short – term strategic shifts that could unsettle operations and capital allocation in 2025/2026.
Model strengths versus vulnerabilities
Pacira company benefits from a long IP moat and favorable market trends for non – opioid options, but reliance on a single flagship product and concentrated distributor relationships leave the Pacira business model exposed to governance shocks and revenue swings.
- Long – term exclusivity: patent settlement extends EXPAREL Pacira protection to 2039
- Clinical/market edge: liposomal bupivacaine mechanism of action supports adoption in opioid – sparing protocols
- Dependency: top three wholesalers represent ~78-79% of revenue, creating concentration risk
- Exposure: activist pressure and potential sale process make the model vulnerable in 2025/2026
For detail on corporate ownership and context see Who Owns Pacira Company
Pacira VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Pacira sells non-opioid pain management products centered on extended-release local analgesics and nerve treatments. Its main offerings are EXPAREL for postsurgical pain, ZILRETTA for osteoarthritis knee pain, and iovera for cryoneurolysis and temporary pain relief.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.